Skip to content
Bored Studies
RecruitingAccepts healthy volunteersEarly Phase 1

Prenatal Aspirin and Postpartum Vascular Function

Anna Stanhewicz, PhD · NCT05653973

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–50 · Women only
Healthy volunteers
Accepted
Study type
Interventional · Early Phase 1
Target enrollment
60
US sites recruiting
1
Study start
January 3, 2023
Record last updated
May 31, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Preeclampsia is a pregnancy disorder affecting \~5-10% of pregnancies in the United States. Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to blood vessel damage and increased inflammation that occurs during the preeclamptic pregnancy and persists postpartum. Low dose aspirin (LDA; 75-150mg/daily) is currently the most effective and clinically accepted therapy for reducing preeclampsia prevalence in women at high risk for developing the syndrome. The purpose of this study is to interrogate the mechanisms by which LDA therapy mitigates persistent vascular dysfunction in postpartum women who have had preeclampsia.

In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) they examine the blood vessels in a dime-sized area of the skin in women who have had a history of preeclampsia. As a compliment to these measurements, they also draw blood from the subjects and isolate the inflammatory cells.

Being studied: Acetylcholine; Endothelin-1

Conditions: Preeclampsia; Microvascular Function

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion

  • 18 years or older,
  • 12 weeks to 5 years postpartum
  • and one of the following:
  • women who had a normal pregnancy and did not use low does aspirin (LDA) during pregnancy,
  • women who had a normal pregnancy and used LDA during pregnancy,
  • women who had preeclampsia and did not use LDA during pregnancy,
  • women who had preeclampsia and used LDA during pregnancy.

Exclusion

  • current daily aspirin use,
  • skin diseases,
  • current tobacco use,
  • diagnosed or suspected hepatic or metabolic disease including chronic kidney disease (CKD) defined as reduced eGFR \< 60 mL/min/1.73m2,
  • statin or other cholesterol-lowering medication,
  • current antihypertensive medication,
  • history of hypertension prior to pregnancy,
  • history of gestational diabetes,
  • current pregnancy,
  • body mass index \<18.5 kg/m2,
  • allergy to materials used during the experiment.(e.g. latex),
  • known allergies to study drugs.

Recruiting US locations

  • University of Iowa

    Iowa City, IA 52242

    Site contact: Anna Stanhewicz, PhD · 319-467-1732 · anna-stanhewicz@uiowa.edu

Study contacts (from the official record)

  • Anna Reid-Stanhewicz, PHD · 319-467-1732 · anna-stanhewicz@uiowa.edu
All pregnancy studies in Iowa →
Prenatal Aspirin and Postpartum Vascular Function (NCT05653973) | Bored Studies